Screen Shot 2017-10-03 at 12.02.40 PM.png

Who We Are

Patients are at the beginning, middle, and heart of all we do.

Harmony Biosciences is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases. With an emphasis on Central Nervous System (CNS) disorders, our goal is to push the boundaries of what science can do to improve the lives of patients.


What We Believe

Our primary mission is to have a positive impact on the lives of those who are so often underserved. We believe it takes both scientific vision and tenacity to pursue new therapies that will have the potential to transform the lives of patients.


Where We’re Starting

Our initial work is focused on Central Nervous System (CNS) disorders. We are proud to be partnering with Dr. Jeanne-Marie Lecomte and Prof. Jean-Charles Schwartz, co-founders of French company Bioprojet SCR (Bioprojet), to develop, register, and market the drug pitolisant, a selective histamine H3-receptor antagonist/inverse agonist for the potential treatment of adult narcolepsy. Currently, no H3-receptor antagonist/inverse agonist has been approved by the US Food & Drug Administration (FDA).

We believe there is tremendous potential in this receptor and we are both proud and excited to be a part of the prospective novel treatments it might offer.



In clinical trials conducted in patients with narcolepsy, the most frequent adverse drug reactions (ADRs) reported with pitolisant were insomnia (8.4%), headache (7.7%), nausea (4.8%), anxiety (2.1%), irritability (1.8%), dizziness (1.4%), depression (1.3%), tremor (1.2%), sleep disorders (1.1%), fatigue (1.1%), vomiting (1.0%), vertigo (1.0%), dyspepsia (1.0%), weight increase (0.9%), and upper abdominal pain (0.9%). Pitolisant is contraindicated in patients with severe hepatic impairment (Child-Pugh C) and in women breastfeeding their children.


Our Leadership

Our company is led by a passionate team of industry veterans with a proven track record of developing and commercializing safe and effective treatments and delivering them to patients with the utmost urgency.

Screen Shot 2017-09-29 at 12.03.03 PM.png

Harmony Biosciences Management Team

Bob Repella


Read More


John Jacobs

EVP & Chief Commercial Officer

Read More

Andrew Serafin

SVP Business Development & Corporate Strategy

Read More

Nancy Lauby

Vice President, Human Resources

Read More

Jeffrey M. Dayno

EVP & Chief Medical Officer

Read More


Board of Directors


Jeffrey Aronin

Read More

Martin Edwards

Read More

Wilbur H. Gantz

Read More

Antonio Gracias

Read More



Read More

Aaron Royston

Read More

Juan Sabater

Read More

Andreas Wicki

Read More





October 5, 2017

Harmony Biosciences Acquires US Rights To Pitolisant From Bioprojet; Raises $270 Million In Equity Financing

Read More